Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 16, Issue 3, Pages 273-278
Publisher
Informa UK Limited
Online
2016-02-07
DOI
10.1586/14737140.2016.1151356
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The choice of first-line Chronic Myelogenous Leukemia treatment
- (2015) Carmen Fava et al. ANNALS OF HEMATOLOGY
- The interferon-alpha revival in CML
- (2015) Moshe Talpaz et al. ANNALS OF HEMATOLOGY
- Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia
- (2015) Delphine Rea ANNALS OF HEMATOLOGY
- Is there a best TKI for chronic phase CML?
- (2015) R. A. Larson BLOOD
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Chronic myeloid leukaemia
- (2015) Jane F Apperley LANCET
- OCT1 and imatinib transport in CML: is it clinically relevant?
- (2015) D B Watkins et al. LEUKEMIA
- Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
- (2015) F Castagnetti et al. LEUKEMIA
- The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
- (2015) V S Hoffmann et al. LEUKEMIA
- Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
- (2015) M Pfirrmann et al. LEUKEMIA
- Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
- (2015) L Kalmanti et al. LEUKEMIA
- How I treat newly diagnosed chronic myeloid leukemia in 2015
- (2014) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
- (2014) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
- (2014) S. Branford et al. BLOOD
- Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
- (2014) B Hanfstein et al. LEUKEMIA
- Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
- (2013) P. Jain et al. BLOOD
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
- (2013) E. Jabbour et al. BLOOD
- BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein
- (2013) Pietro Buffa et al. FASEB JOURNAL
- Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
- (2013) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors
- (2013) Massimo Breccia et al. LEUKEMIA RESEARCH
- Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib
- (2013) Alfonso Quintás-Cardama et al. LEUKEMIA RESEARCH
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
- (2012) B Hanfstein et al. LEUKEMIA
- Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia
- (2012) Juan Luis Steegmann et al. LEUKEMIA & LYMPHOMA
- Towards a need to a “biological Sokal risk” in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia
- (2012) Fabio Stagno et al. LEUKEMIA RESEARCH
- Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
- (2011) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
- (2011) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
- (2011) Carlo Gambacorti-Passerini et al. JNCI-Journal of the National Cancer Institute
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
- (2010) T. P. Hughes et al. BLOOD
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
- (2010) Amie S. Corbin et al. JOURNAL OF CLINICAL INVESTIGATION
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Who is in charge of assessing therapeutic drug monitoring? The case of imatinib
- (2010) Thierry Buclin et al. LANCET ONCOLOGY
- Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase
- (2009) Yesid Alvarado et al. CANCER
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia
- (2009) J E Cortes et al. LEUKEMIA
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
- (2008) R. A. Larson et al. BLOOD
- Part I: Milestones in personalised medicine—imatinib
- (2008) Carlo Gambacorti-Passerini LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now